Price
CHART BY
Frequently asked questions
What is BioMarin Pharma's market capitalization?
The market capitalization of BioMarin Pharma is $12.88B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is BioMarin Pharma's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for BioMarin Pharma is 179.37. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for BioMarin Pharma?
BioMarin Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.371. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for BioMarin Pharma's stock?
Currently, 30 analysts cover BioMarin Pharma's stock, with a consensus target price of $91.48. Analyst ratings provide insights into the stock's expected performance.
What is BioMarin Pharma's revenue over the trailing twelve months?
Over the trailing twelve months, BioMarin Pharma reported a revenue of $3.46B.
What is the EBITDA for BioMarin Pharma?
BioMarin Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $792.51M. EBITDA measures the company's overall financial performance.
What is the free cash flow of BioMarin Pharma?
BioMarin Pharma has a free cash flow of $738.18M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does BioMarin Pharma have, and what sector and industry does it belong to?
BioMarin Pharma employs approximately 3,221 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of BioMarin Pharma's shares?
The free float of BioMarin Pharma is 191.08M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $12.88B
- EPS (TTM)
- $0.371
- Free Float
- 191.08M
- P/E ratio (TTM)
- 179.37
- Revenue (TTM)
- $3.46B
- EBITDA (TTM)
- $792.51M
- Free Cashflow (TTM)
- $738.18M
Pricing
- 1D span
- $66.44$66.89
- 52W span
- $49.29$70.98
Analyst Ratings
The price target is $91.48 and the stock is covered by 30 analysts.
Buy
23
Hold
7
Sell
0
Information
BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
- Employees
- 3,221
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- BMRN
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet